Granulocyte‐Macrophage Colony‐Stimulating Factor Augments Phagocytosis ofMycobacterium aviumComplex by Human Immunodeficiency Virus Type 1–Infected Monocytes/Macrophages In Vitro and In Vivo
Author(s) -
Katherine Kedzierska,
Johnson Mak,
Anne Mijch,
Ian R. C. Cooke,
Melissa Rainbird,
Sally Roberts,
Geza Paukovics,
Damien Jolley,
Angel F. López,
Suzanne M. Crowe
Publication year - 2000
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/315191
Subject(s) - phagocytosis , macrophage , biology , immunology , microbiology and biotechnology , monocyte , in vitro , in vivo , macrophage colony stimulating factor , granulocyte , biochemistry
The role of human immunodeficiency virus type 1 (HIV-1) infection on the ability of human monocytes/macrophages to phagocytose Mycobacterium avium complex (MAC) in vivo and in vitro and the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on this function were investigated. By use of a flow cytometric assay to quantify phagocytosis, HIV-1 infection was found to impair the ability of monocyte-derived macrophages to phagocytose MAC in vitro, whereas GM-CSF significantly improved this defect. Phagocytosis was not altered by exposure to a mutant form of GM-CSF (E21R) binding only to the alpha chain of the GM-CSF receptor, suggesting that signaling by GM-CSF that leads to augmentation of phagocytosis is via the beta chain of the receptor. In a patient with AIDS and disseminated multidrug-resistant MAC infection, GM-CSF treatment improved phagocytosis of MAC by peripheral blood monocytes and reduced bacteremia. These results imply that GM-CSF therapy may be useful in restoring antimycobacterial function by human monocytes/macrophages.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom